By David Bautz, PhD NASDAQ:IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with the U.S. Food and Drug Administration (FDA) following an ‘End-of-Phase 2’ meeting on the company’s proposed plan for a Phase … Read more
By David Bautz, PhD NASDAQ:FBLG READ THE FULL FBLG RESEARCH REPORT Business Update On Track to Initiate Phase 1/2 Trial in Diabetic Foot Ulcers FibroBiologics, Inc. (NASDAQ:FBLG) is on track to initiate a Phase 1/2 trial of CYWC628, a fibroblast-based spheroid product candidate, in patients suffering from diabetic foot ulcers (DFU) in the second quarter … Read more
By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Enterprise Replace Part 3 PALISADE Outcomes Revealed in The New England Journal of Drugs On September 2, 2024, Arrowhead Prescribed drugs, Inc. (NASDAQ:ARWR) introduced outcomes for the Part 3 PALISADE trial of plozasiran in sufferers with familial chylomicronemia syndrome (FCS). The outcomes had been … Read more
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Enterprise Replace Part 3 ALS Trial Ongoing MediciNova, Inc. (NASDAQ:MNOV) is at the moment evaluating MN-166 (ibudilast) in a Part 3 scientific trial for amyotrophic lateral sclerosis (ALS). The trial initiated in 2019 and, if profitable, outcomes from this trial are anticipated to assist … Read more
